Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to ...

Labcorp expanded its partnership with PathAI to offer its FDA-cleared digital pathology platform at the life science giant’s U.S. network of anatomical pathology labs and participating hospitals.

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...

Labcorp said it will be using the company's FDA-cleared AISight Dx platform across its national network of anatomic pathology labs and hospital collaborations.